For researchers expanding inhibitor discovery beyond conventional formats, our Alternative Scaffolds capabilities include phage display for Kunitz domain inhibitor discovery service, which is designed to help identify Kunitz-based binders and research-stage inhibitory candidates, particularly for proteases and protease-related discovery programs. At Creative Biolabs, we support projects from library strategy and target-driven selection to clone confirmation, recombinant production, and project-dependent functional assessment, enabling a practical route for protein engineering, mechanism study, and early candidate evaluation.
Fig.1 Phage display workflow for Kunitz domain inhibitor screening and validation.
Kunitz domains are compact inhibitory scaffolds with a well-established role in protease recognition, especially in protease-focused research. Their size, structural stability, disulfide-constrained architecture, and engineerable reactive regions make them attractive for discovery programs that require focused affinity selection, specificity tuning, and activity profiling. In research settings, they are widely explored for protease function analysis, pathway interrogation, and the identification of binders or inhibitory candidates with defined sequence-function relationships.
Yet many discovery teams face the same challenges. Native inhibitors may not match the required selectivity window. Rational redesign alone often misses productive sequence space. Functional follow-up can become slow when too many variants fail to express, fold, or retain target-relevant activity. When target families are closely related, weak discrimination between homologous proteases can further delay progress. A phage display workflow built around Kunitz variant libraries helps address these bottlenecks by linking genotype to phenotype, enabling controlled enrichment under target-specific screening pressure, and creating a practical starting point for downstream recombinant confirmation and inhibition testing.
If your program requires a tailored inhibitor discovery strategy, you can share your target and project goals with our team for a customized study design.
Creative Biolabs offers an integrated service for Kunitz domain inhibitor discovery, supporting researchers from scaffold design to research-stage functional assessment. This service is particularly suitable for de novo discovery, focused sequence optimization, and target-oriented screening in protease or protease-related research programs. For non-protease or noncanonical targets, project outputs are more commonly positioned toward binder discovery, interaction analysis, or scaffold evaluation, depending on target compatibility and study scope.
Our service can include:
Depending on your research objective, the study can be tailored for broad exploratory screening or a more focused campaign built around known target biology, existing lead sequences, parental Kunitz scaffolds, or predefined assay requirements. Final recovery of functional inhibitory candidates depends on target properties, library design, and assay format. Validation depth may vary by project scope and assay feasibility. This allows clients to obtain a practical and well-structured dataset for downstream inhibitor research, candidate triage, and sequence-guided follow-up engineering.
Our project workflow is designed to keep the study streamlined, transparent, and easy to manage from kickoff to final data delivery, while preserving the scaffold-specific considerations that matter in Kunitz-domain discovery.
We review the target class, research goal, available materials, assay context, and desired output to assess whether a Kunitz scaffold is appropriate for the project and whether competitive selection, counter-selection, or downstream inhibition testing should be built into the study design.
Variable regions, reactive loops, and candidate engineering positions are defined while preserving key scaffold features such as conserved cysteines and fold-supporting architecture. Library format, diversification scope, and target-specific screening conditions are then established based on the agreed project plan.
Phage display screening is performed using target-specific panning conditions, with enrichment monitoring and counter-selection against off-targets or closely related proteases when appropriate, followed by recovery of enriched clone populations.
Recovered clones are sequenced, de-duplicated, and analyzed for enrichment patterns, recurring motifs, and project-relevant sequence features to prioritize binders or candidate inhibitory variants for follow-up work.
Selected candidates can move into recombinant production, binding confirmation, target-specific inhibition assays, and preliminary selectivity assessment when included in the project scope and technically feasible within a research-use workflow.
All agreed results are compiled into a structured delivery package, together with project records, interpretation notes, and recommended next-step options such as focused re-screening, sequence refinement, or expanded characterization where applicable.
To discuss a project plan matched to your target and research scope, you may contact our team or request a quotation.
Typical starting materials include purified target proteins, activated proteases, tagged target constructs, immobilized target preparations, or validated target-related assay systems. If you already have a parental Kunitz sequence, preliminary binders, mutational hypotheses, or known negative targets for counter-selection, we can incorporate them into a focused engineering plan. For clients who do not yet have optimized target material, upstream target preparation and assay development can also be discussed as part of project setup.
Deliverables are defined according to the selected package, but a standard project handover may include library construction summary, panning records, sequence data for enriched clones, candidate ranking results, recombinant production summary, and project-dependent assay data generated within the agreed research scope. Depending on study design, outputs may range from enriched sequence datasets to binder confirmation data or functional inhibition results. Supporting documentation can be organized to facilitate internal review, next-round engineering, or transfer into your own downstream validation pipeline.
Our handover process is designed to keep decision-making straightforward. After internal quality review, we compile data into a structured report, discuss key findings with your team, and highlight recommended next actions such as re-screening, focused maturation, selectivity refinement, or expanded characterization. This format is particularly useful when multiple candidate sequences must be triaged efficiently.
To start your study, you may share your target information with our team, request a formal quote, or discuss a customized screening package.
Recent literature continues to support the biological relevance and engineerability of the Kunitz scaffold for inhibitor research. A study published in 2025 described a Kunitz-domain peptide, Shp4, with potent factor XIa inhibitory activity and further mapped sequence-function relationships through mutational analysis. These findings support the value of Kunitz scaffolds in target-focused inhibitor research and highlight why sequence-guided engineering, hotspot-focused optimization, and library-based discovery workflows such as phage display can be scientifically well justified in follow-up programs. This published study supports the scaffold rationale and structure-function understanding, rather than directly validating the phage display workflow itself.
Fig.2 Representative published data illustrating Kunitz-domain structure-function relationships
in FXIa-related inhibitor research.1
For service planning, this type of published evidence can inform how loop diversification is prioritized, how mutational hotspots are selected for focused optimization, and why structure-function knowledge can support rational follow-up engineering after screening.
If you are evaluating whether a Kunitz scaffold is suitable for your target, you can consult Creative Biolabs for project-specific recommendations on library scope, screening design, and downstream validation options.
Q: Can this service be used for proteases other than classical serine proteases?
A: Yes. Kunitz-domain discovery is particularly relevant for protease-focused research, including programs involving classical serine proteases and other compatible protease targets. For these projects, the workflow can be configured toward inhibitor-oriented discovery, recombinant confirmation, and project-dependent functional testing.
Q: Can this workflow be adapted for non-protease or noncanonical targets?
A: In some cases, yes. For non-protease or noncanonical targets, Kunitz-based projects are more commonly positioned toward binder discovery, interaction analysis, or scaffold evaluation. Whether a functional inhibitory outcome is realistic depends on target biology, assay format, and overall project scope.
Q: Do I need to provide an existing Kunitz sequence to start?
A: No. Projects can begin from a new library concept or from an existing parental sequence. If you already have sequence preferences, structural data, lead variants, or defined engineering hypotheses, those inputs can be used to build a more focused campaign.
Q: Can you help validate the selected clones after panning?
A: Yes. We can extend the workflow from clone sequencing to recombinant expression, binding confirmation, and project-dependent functional testing so that enriched candidates are supported by experimental follow-up data rather than sequence information alone.
Q: Are the outputs intended for therapeutic or diagnostic use?
A: No. All services, data, and materials are provided for scientific research use only and are not intended for clinical diagnosis, treatment, or direct medical application.
Reference:
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
